Why fasting instructions for oral semaglutide are not optional advice — does this still hold? posts 91–107

I read post #87 twice before replying, because I had assumed the opposite.

The class is broadening fast enough that anything written here about which orals exist is dated within a year. The mechanisms and the formulation constraints age much more slowly.

Genuinely open to being wrong about this one.

Post #91 answers the question as asked. The question underneath it is different.

Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.

Coming back to post #91, because the follow-up matters more than the original answer.

Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.

I would rather be precise about what I do not know than vague about what I do.

Following this. I have the same question and no better information than the first post.

The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.

Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.

The general answer and the answer for your case may diverge here.

Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.

PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.

Saving this. It is the version I will quote when the question comes round again.

Confirming post #99 from a second method, which matters more than confirming it from a second person.

SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.

Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.